GlassScriptPhysician profile
Jeffrey W Johnson
NPI 1285692400
$2,630.96
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,677 · 2020: $342 · 2021: $612.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $363.62 | 2019-2021 | |
| Pfizer INC. | $274.17 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $202.37 | 2019-2021 | |
| Allergan, INC. | $199.85 | 2019-2020 | |
| Novo Nordisk INC | $194.06 | 2019-2021 | |
| Abbvie INC. | $161.49 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $157.94 | 2019-2021 | |
| Lilly USA, LLC | $149.08 | 2019-2021 | |
| Amgen INC. | $144.27 | 2019-2021 | |
| Medtronic USA, INC. | $123.74 | 2019 | |
| Astellas Pharma US INC | $112.85 | 2019-2020 | |
| Daiichi Sankyo INC. | $105.02 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $99.61 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $49.71 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $45.20 | 2019-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $42.50 | 2019 | |
| Abbott Laboratories | $37.42 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $35.96 | 2019-2020 | |
| Amarin Pharma, INC. | $31.55 | 2021 | |
| Dexcom, INC. | $20.19 | 2021 | |
| Antares Pharma, INC. | $16.87 | 2021 | |
| Becton, Dickinson and Company | $15.82 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $12.72 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.10 | 2019 | |
| Eisai INC. | $11.55 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $11.30 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.